Sample Content Directory Federated States of Micronesia

Thursday, September 22, 2016

Pompaton

Pompaton may be available in the countries listed below.

Ingredient matches for Pompaton

Famotidine

Famotidine is reported as an ingredient of Pompaton in the following countries:

Indonesia

International Drug Name Search

Bromocriptine Mesylate

Class: Ergot-derivative Dopamine Receptor Agonists
ATC Class: G02CB01
VA Class: AU900
CAS Number: 22260-51-1
Brands: Parlodel

Introduction

Ergot-derivative dopamine receptor agonist and prolactin inhibitor.^a ^b

Uses for Bromocriptine Mesylate

Hyperprolactinemic Disorders

Treatment of male and female dysfunctions associated with hyperprolactinemia, including amenorrhea and/or galactorrhea, hypogonadism, and infertility.^a ^b

Used in patients with prolactin-secreting adenomas (e.g., prolactinoma), including macroadenomas, to decrease tumor size; may be used prior to surgery in patients undergoing excision of the tumor (adenectomy).^a ^b

Treatment of female infertility associated with hyperprolactinemia; used to induce ovulation in appropriately selected anovulatory women.^b

Treatment of hypogonadism and galactorrhea that persist following radiation therapy or surgery in hyperprolactinemic males with prolactin-secreting adenomas and adequate testosterone concentrations.^a ^b Some clinicians consider bromocriptine the treatment of choice for reduction of large tumors (macroadenomas).^b

Parkinsonian Syndrome

Symptomatic management of idiopathic or postencephalitic parkinsonian syndrome.^a ^b

Used as an adjunct to levodopa for the symptomatic management of parkinsonian syndrome in patients with advanced disease.¹¹¹ ¹¹² ^a

Has been used as monotherapy for initial symptomatic management of parkinsonian syndrome†.¹¹¹ Most clinicians would use levodopa for initial therapy in individuals >70 years of age (less likely than younger individuals to develop levodopa-related motor complications and because of concerns about cognitive dysfunction), in patients with cognitive impairment, and in those with severe disease.¹¹¹ A dopamine receptor agonist may be preferred for initial therapy in patients ≤70 years of age.¹¹¹

Acromegaly

Treatment of acromegaly, alone or as adjunctive therapy with pituitary irradiation or surgery.^a ^b

Male Infertility

Has been used to increase sperm counts and restore fertility† in oligospermic men without hyperprolactinemia who are unresponsive to traditional drug therapy.^b

Neuroleptic Malignant Syndrome

Has been used to relieve extrapyramidal reactions, hyperthermia, and hypertension of neuroleptic malignant syndrome† (NMS) associated with neuroleptic drug therapy (e.g., haloperidol, fluphenazine).^b

Hepatic Encephalopathy

Has been used in the management of chronic hepatic encephalopathy†.^b

Postpartum Breast Engorgement

Used in the past for prevention of postpartum breast engorgement†;¹⁰⁶ ^b FDA has withdrawn approval of bromocriptine for this indication because the risk of serious, potentially fatal adverse effects¹⁰⁰ ¹⁰² ¹⁰⁴ ¹⁰⁷ ¹⁰⁸ outweigh the limited benefits associated with this use.¹⁰¹ ¹⁰³ (See Cardiovascular Effects under Cautions.)

Bromocriptine Mesylate Dosage and Administration

General

Individualize and adjust dosage carefully; evaluate frequently during dosage adjustment to determine lowest therapeutic dosage.^a ^b

Temporary dosage reduction or discontinuance may be necessary in patients developing intolerable adverse effects.^b

When bromocriptine is discontinued (i.e., during pregnancy) in patients being treated for hyperprolactinemic disorders, monitor patients for tumor progression or development.^b (See Warnings: Pregnancy under Cautions.)

Hyperprolactinemic Disorders

During initial therapy for female infertility, use a mechanical contraceptive in conjunction with bromocriptine therapy until normal ovulatory menstrual cycles have been restored; contraception can then be discontinued.^a ^b

If menstruation does not occur within 3 days of the expected date, discontinue bromocriptine and perform a pregnancy test.^a ^b

Parkinsonian Syndrome

Assess patient’s therapeutic response at 2-week intervals to ensure lowest effective dosage is not exceeded.^a ^b

Acromegaly

Determine serum growth hormone concentrations monthly, and adjust bromocriptine dosage based on the reduction in these concentrations and the patient’s clinical response.^a ^b

If an adequate response is not apparent after a brief trial with the drug and/or dosage adjustment and clinical evaluation, consider discontinuance of bromocriptine.^a ^b

Withdraw therapy (4- to 8-week period is usually adequate) annually in patients undergoing radiation therapy of the pituitary to determine if continued therapy with the drug and/or radiation is necessary.^a ^b If signs and/or symptoms of acromegaly recur or growth hormone concentrations increase during this period, consider additional bromocriptine therapy.^a ^b

Administration

Oral Administration

Administer orally with food.^a ^b

Dosage

Available as bromocriptine mesylate; dosage expressed in terms of bromocriptine.^a

Pediatric Patients

Hyperprolactinemic Disorders

Prolactin-secreting Adenomas

Oral

Children ≥11 years of age: Initially, 1.25–2.5 mg daily.^a May increase as tolerated until therapeutic response achieved.^a Usual dosage range is 2.5–10 mg daily.^a

Adults

Hyperprolactinemic Disorders

Amenorrhea, Galactorrhea, Female Infertility

Oral

Initially, 1.25–2.5 mg daily.^a ^b May increase dosage by 2.5 mg every 2–7 days, as tolerated, until therapeutic response achieved.^a Usual dosage range is 2.5–15 mg daily;^a up to 30 mg daily has been required in some patients with amenorrhea and/or galactorrhea.^b

Hypogonadism and Galactorrhea in Males

Oral

Prolactin-secreting Adenomas

Oral

Initially, 1.25–2.5 mg daily.^b May increase dosage by 2.5 mg every 2–7 days, as tolerated, until therapeutic response achieved.^a Usual dosage range is 2.5–15 mg daily.^a

Parkinsonian Syndrome

Oral

Initially, 1.25 mg twice daily with meals.^a ^b If needed, may increase dosage by 2.5 mg daily every 14–28 days; do not exceed 100 mg daily.^a ^b

If levodopa dosage reduced because of adverse effects, may increase daily dosage of bromocriptine gradually in 2.5-mg increments.^a ^b

Acromegaly

Oral

Initially, 1.25–2.5 mg at bedtime for 3 days.^a ^b May increase dosage by 1.25–2.5 mg daily at 3- to 7-day intervals, as tolerated, until desired therapeutic benefit achieved.^a ^b

Reevaluate patients monthly, adjust dosage based on reduction of growth hormone or clinical response.^a ^b Usual dosage range is 20–30 mg daily; do not exceed 100 mg daily.^a ^b Dosages of 20–60 mg have been administered daily in divided doses.^b

Neuroleptic Malignant Syndrome†

Oral

2.5–5 mg 2–6 times daily.^b

Hepatic Encephalopathy†

Oral

Initially, 1.25 mg daily; increase dosage by 1.25 mg daily every third day up to a total maintenance dosage of 15 mg daily.^b

Prescribing Limits

Safety of dosages >100 mg daily not established.^a ^b

Adults

Parkinsonian Syndrome

Oral

Maximum 100 mg daily.^a ^b Safety of therapy for >2 years not established.^a ^b

Special Populations

Hepatic Impairment

Decreased clearance; dosage adjustment may be necessary.^a (See Elimination under Pharmacokinetics)

Cautions for Bromocriptine Mesylate

Contraindications

Uncontrolled hypertension.^a ^b (See Cardiovascular Effects under Cautions.)

Known sensitivity to ergot alkaloids.^a ^b

Known hypersensitivity to bromocriptine or any ingredient in the formulation.^a

Warnings/Precautions

Warnings

Pregnancy

Mechanical contraceptive measures recommended for women not seeking pregnancy or those with large adenomas.^a ^b Perform pregnancy test every 4 weeks in amenorrheic women and, once menses are reinstated, whenever a menstrual period is missed.^a ^b

Possible sudden enlargement of underlying prolactin-secreting pituitary tumors in women with hyperprolactinemic disorders who become pregnant and discontinue bromocriptine therapy; may result from normal increases in pituitary size during pregnancy.^a ^b May cause optic nerve compression, visual impairment, or blindness, which usually disappear after delivery; regular visual field checks recommended.^a ^b Diabetes insipidus and pituitary apoplexy also may occur.^a ^b Prior to initiating therapy for amenorrhea/galactorrhea and infertility, carefully evaluate the pituitary including gadolinium-enhanced MRI to rule out pituitary tumors.^a ^b ^c

Discontinue therapy immediately if pregnancy occurs during therapy for hyperprolactinemic disorders and carefully observe women throughout pregnancy for signs and symptoms of tumor progression.^a ^b If reinstitution of therapy is required to control a rapidly expanding macroadenoma and a hypertensive disorder associated with pregnancy occurs, consider risks and benefits of continuing bromocriptine therapy.^a (See Cardiovascular Effects under Cautions.)

If pregnancy occurs in a woman receiving therapy for acromegaly or parkinsonian syndrome, discontinue therapy unless bromocriptine therapy is medically necessary.^a If therapy is continued and a hypertensive disorder of pregnancy occurs, discontinue therapy unless bromocriptine withdrawal is medically contraindicated.^a ^b

Only continue bromocriptine during the postpartum period in women with a cardiovascular disease history if withdrawal is considered medically contraindicated; carefully observe the patient.^a

Somnolence

Episodes of falling asleep while engaged in activities of daily living, sometimes without warning or awareness, have been reported, particularly in patients with parkinsonian syndrome.^a Consider dosage reduction or treatment discontinuance if these effects occur.^a

Cardiovascular Effects

Symptomatic hypotension reported, especially during initial treatment; use caution, especially during the first days of treatment.^a ^b

Hypertension (sometimes developing with initiation of therapy but often during the second week), seizures, and potentially fatal strokes reported, mostly in postpartum women.^a Acute MI reported rarely.^a

Seizures and strokes usually preceded by a constant and severe headache hours to days prior to event and may be preceded by visual disturbances (blurred vision, transient cortical blindness).^a ^b

Discontinue therapy immediately and evaluate patient promptly if hypertension; severe, progressive, or unremitting headache (with or without visual disturbances); or evidence of CNS toxicity occurs.^a ^b

Periodic monitoring of BP recommended, especially during the first few weeks of therapy.^a

Use with caution in patients with a history of cardiovascular disease or MI with residual atrial, nodal, or ventricular arrhythmia.^a ^b

Fibrotic Effects

Pleural and pericardial effusions, constrictive pericarditis, and pleural and pulmonary fibrosis reported, especially in patients receiving high-dose, long-term therapy; usually resolves slowly with discontinuance of therapy.^a ^b Consider discontinuance of therapy if these disorders occur.^a

Observe patients receiving long-term (e.g., 6–36 months), high-dose (e.g., 20–100 mg daily) therapy for pulmonary changes (e.g., infiltrates, effusion, and thickening of the pleura).^a ^b Thoroughly evaluate unexplained pleuropulmonary disorders and consider discontinuance of therapy.^a

Retroperitoneal fibrosis reported rarely in patients receiving long-term (e.g., 2–10 years), high-dose (30–140 mg daily) therapy.^a ^b Monitor for manifestations (e.g., back pain, lower extremity edema, impaired kidney function); discontinue therapy if fibrotic changes are diagnosed or suspected.^a

General Precautions

Nervous System Effects

Confusion and mental disturbances may occur in patients with parkinsonian syndrome receiving high-dose therapy; usually resolve within 2–3 weeks after discontinuance.^a Use caution in patients who manifest mild dementia.^a

Visual or auditory hallucinations reported in patients with parkinsonian syndrome; hallucinations usually resolve following dosage reduction, but discontinuance of drug may occasionally be necessary.^a ^b Rarely, hallucinations may persist for several weeks following discontinuance of the drug.^a ^b Use with caution in patients with a history of psychosis.^a

CSF rhinorrhea reported rarely in patients with prolactin-secreting adenomas who previously underwent transsphenoidal surgery and/or radiation therapy and who were receiving the drug for tumor recurrence; may also occur in patients with previously untreated prolactinoma that extends into the sphenoid sinus.^a ^b

Lactose Intolerance

Use not recommended in patients with galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption.^a

Ocular Effects

Secondary visual field loss due to chiasmal herniation may occur in patients with macroprolactinoma effectively treated for hyperprolactinemia.^a ^b Monitor patients and consider decreasing dosage if this occurs.^a

Relative efficacy of bromocriptine therapy versus surgery in preserving the visual fields in patients with hyperprolactinemic disorders not known.^a ^b Patients with rapidly progressing visual field loss should be evaluated by a neurosurgeon.^a ^b

Digital Vasospasm

Cold-sensitive digital vasospasm reported in patients being treated for acromegaly; usually resolves following a reduction in dosage and may be prevented by keeping fingers warm.^a

Growth Hormone-secreting Tumors

Possible expansion of growth hormone-secreting tumors in patients with acromegaly.^a ^b Careful monitoring recommended; if evidence of tumor expansion occurs, discontinue therapy and consider alternative therapies.^a ^b

Adequate Patient Monitoring

Evaluate hepatic, hematopoietic, cardiovascular, and renal function periodically in patients receiving prolonged therapy with bromocriptine (e.g., treatment of parkinsonian syndrome).^a

GI Bleeding

Severe GI bleeding from peptic ulcers, sometimes fatal, reported in patients with acromegaly.^a ^b Closely monitor patients with a history of peptic ulcer or GI bleeding.^a ^b Thoroughly evaluate signs and symptoms of peptic ulcer; institute appropriate therapy if necessary.^a ^b

Specific Populations

Pregnancy

Category B.^a (See Warnings: Pregnancy under Cautions.)

Lactation

Use not recommended in nursing women because bromocriptine interferes with lactation.^a ^b

Pediatric Use

Safety and efficacy established for children ≥16 years of age for treatment of prolactin-secreting adenomas.^a However, bromocriptine has been evaluated in well-controlled clinical trials in children ≥11 years of age.^a

Safety and efficacy not established for other uses.^a

Geriatric Use

Insufficient experience in clinical trials with patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults; consider age-related decreases in hepatic, renal, or cardiac function in this population.^a ^b

Hepatic Impairment

Use with caution; safety and efficacy not established.^a ^b Reduced dosage may be required.^a ^b

Renal Impairment

Use with caution; safety and efficacy not established.^a ^b

Common Adverse Effects

Patients with hyperprolactinemia: Nausea, headache, fatigue, dizziness, lightheadedness, vomiting, abdominal cramps, constipation, diarrhea, drowsiness, nasal congestion.^a

Patients with acromegaly: Nausea, constipation, postural/orthostatic hypotension, anorexia, dry mouth/nasal stuffiness, indigestion/dyspepsia, digital vasospasm, drowsiness.^a

Patients with parkinsonian syndrome: Nausea, involuntary movements, hallucinations, confusion, “on-off” episodes, dizziness, drowsiness, faintness/fainting, vomiting, asthenia, abdominal discomfort, visual disturbance, ataxia, insomnia, depression, hypotension, shortness of breath, constipation, vertigo.^a

Interactions for Bromocriptine Mesylate

Metabolized principally by CYP3A; potent inhibitor of CYP3A4.^a

Drugs Affecting Hepatic Microsomal Enzymes

Inhibitors of CYP3A4: Potential pharmacokinetic interaction (increased plasma bromocriptine concentrations).^a

Drugs Metabolized by Hepatic Microsomal Enzymes

Potent substrates of CYP3A4: Potential pharmacokinetic interaction (increased plasma substrate concentrations).^a However, not expected to alter metabolism of CYP3A4 substrates, due to low free concentrations of bromocriptine.^a

Drugs That Increase Prolactin Concentrations

Potential inhibition of bromocriptine's effectiveness in reducing serum prolactin concentrations.^a

Specific Drugs

Drug	Interaction	Comments
Alcohol	May potentiate adverse effects of bromocriptine^a Possible decreased alcohol tolerance^b	Limit alcohol intake^a ^b
Antidepressants, tricyclics (amitriptyline, imipramine)	Potential reduced efficacy of bromocriptine ^b	Consider increasing bromocriptine dosage^b
Antifungals, azoles	Possible interference with bromocriptine metabolism^a	Use concomitantly with caution^a
Antihypertensives	Potential additive hypotensive effects^a ^b	Careful adjustment of antihypertensive dosage may be necessary^a ^b Use with caution^a ^b
Antipsychotic agents (haloperidol, phenothiazines)	Possible reduced efficacy of bromocriptine^a ^b	Increased bromocriptine dosage may be required if used concomitantly^b
Butyrophenones (e.g., droperidol)	Potential reduced bromocriptine concentrations^a ^b	Consider increasing bromocriptine dosage^b
Dopamine antagonists (e.g., metoclopromide, pimozide)	Possible reduced efficacy of bromocriptine^a
Ergot alkaloids	Potential for severe adverse effects (e.g., hypertension, myocardial infarction)^a ^b (see Cardiovascular Effects under Cautions)	Concomitant use not recommended^a ^b
HIV protease inhibitors	Possible interference with bromocriptine metabolism^a	Use concomitantly with caution^a
Levodopa	Potential additive therapeutic and neurologic effects^b	May be used to therapeutic advantage; consider decreasing levodopa dosage^b
Macrolide antibiotics (e.g., erythromycin)	Increased plasma bromocriptine concentrations^a
Methyldopa	Possible reduced efficacy of bromocriptine^b	Increased bromocriptine dosage may be required if used concomitantly^b
Octreotide	Increased concentrations of bromocriptine^a
Reserpine	Possible reduced efficacy of bromocriptine^a ^b	Increased bromocriptine dosage may be required if used concomitantly^b

Bromocriptine Mesylate Pharmacokinetics

Absorption

Bioavailability

Absolute bioavailability 28%, with peak plasma concentration usually attained within 1–3 hours.^a

Onset

Following oral administration, onset of prolactin-lowering effect begins within 1–2 hours of ingestion, with maximal benefit within 5–10 hours.^a Parkinsonian effects may begin 30–90 minutes after ingestion, with maximal benefit within approximately 2 hours.^b

Duration

Maximum prolactin-lowering effects generally persist for 8–12 hours.^a

Distribution

Extent

Does not distribute appreciably into erythrocytes.^a ^b

Plasma Protein Binding

90–96% (mainly albumin).^a

Elimination

Metabolism

Undergoes extensive first-pass biotransformation in the liver, primarily via CYP3A and hydroxylation, to form inactive metabolites.^a ^b

Elimination Route

Bromocriptine and its metabolites eliminated principally (85%) in feces via biliary excretion and to a lesser extent (6%) in urine.^a ^b

Half-life

Biphasic; terminal half-life is approximately 15 hours.^a

Special Populations

Hepatic impairment decreases elimination, resulting in increased plasma bromocriptine concentrations.^a

Stability

Storage

Oral

Capsules and Tablets

Tight, light-resistant containers at <25°C.^a

ActionsActions

A dopamine receptor agonist that activates postsynaptic dopamine receptors that modulate the secretion of prolactin from the anterior pituitary. ^a

Substantially reduces serum prolactin concentrations by inhibiting release of prolactin from the anterior pituitary gland; directly affects the pituitary and/or stimulates postsynaptic dopamine receptors in the hypothalamus to release prolactin-inhibitory factor via a complicated catecholamine pathway.^b

Causes transient increases in somatropin (growth hormone) secretion in individuals with normal growth hormone concentrations; paradoxically causes sustained suppression of growth hormone secretion in patients with acromegaly.^a ^b

Relieves symptoms of parkinsonism by directly stimulating dopamine receptors in the corpus striatum;^a ^b dysregulation of brain serotonin activity may also occur.^b

Advice to Patients

Risk of dizziness, drowsiness, or faintness; use caution when driving or operating machinery.^a ^b

Risk of somnolence; possibility of falling asleep during activities of daily living.^a ^b If this occurs, patients should not drive or participate in potentially dangerous activities until episodes resolve.^a ^b

Importance of immediately informing clinician if persistent watery nasal discharge occurs in patients being treated for macroadenoma or in patients who have had recent transsphenoidal surgery.^a

Advise patients being treated for macroadenoma that discontinuance of bromocriptine may result in rapid regrowth of tumor and recurrence of original symptoms.^a

Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as concomitant illnesses, such as hypertension or hypotension.^a

Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.^a ^b

Importance of using a method of contraception and monitoring regular pregnancy tests in patients treated for amenorrhea, as pregnancy may occur prior to the return of menses.^a

Importance of informing patients of other important precautionary information. (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Bromocriptine Mesylate
Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Capsules	5 mg (of bromocriptine)*	Bromocriptine Mesylate Tablets	Sandoz
			Parlodel	Novartis
	Tablets	2.5 mg (of bromocriptine)*	Bromocriptine Mesylate Tablets	Lek, Sandoz
			Parlodel SnapTabs (with povidone; scored)	Novartis

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Bromocriptine Mesylate 2.5MG Tablets (MYLAN): 30/$64.99 or 90/$174.97

Bromocriptine Mesylate 5MG Capsules (MYLAN): 30/$135.99 or 90/$385.97

Parlodel 2.5MG Tablets (NOVARTIS): 30/$165.99 or 90/$497.98

Parlodel 5MG Capsules (NOVARTIS): 30/$259.99 or 90/$709.96

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions November 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

100. Anon. Sandoz withdrawing Parlodel postpartum lactation suppression indication. Prescription Pharm Biotechnol. 1994; 56(Aug 22):T&G1-2.

101. Anon. Bromocriptine indication withdrawn. FDA Med Bulletin. 1994; 24:2.

102. Anon. Sandoz will halt promotion of bromocriptine for suppression of lactation. Am J Hosp Pharm. 1994; 51:2626.

103. Hartwig SC, Smeenk DA, Michaels MR. Drug-use evaluation program for postpartum bromocriptine therapy. Am J Hosp Pharm. 1990; 47:2514-5. [PubMed 2278264]

104. Larrazet F, Spaulding C, Lobreau HJ et al. Possible bromocriptine-induced myocardial infarction. Ann Intern Med. 1993; 118:199-200. [IDIS 308704] [PubMed 8417637]

105. Sandoz, East Hanover, NJ: Personal communication.

106. Sandoz. Parlodel (bromocriptine mesylate) Snap-Tabs tablets and capsules prescribing information dated Sep 1993. In: Physicians’ desk reference. 49th ed. Montvale, NJ: Medical Economics Company, Inc. 1994:2178-80.

107. Rothman KJ, Funch DP, Dreyer NA. Bromocriptine and puerperal seizures. Epidemiology. 1990; 1:232-8. [PubMed 2081258]

108. Eickman FM. Recurrent myocardial infarction in a postpartum patient receiving bromocriptine. Clin Cardiol. 1992; 15:781-3. [PubMed 1395192]

109. Gittelman D. Bromocriptine associated with postpartum hypertension, seizures, and pituitary hemorrhage. Gen Hosp Psychiatry. 1991; 13:278-80. [PubMed 1874430]

110. Food and Drug Administration. Sandoz Pharmaceutical Corp.; Bromocriptine mesylate (Parlodel); withdrawal of approval of the indication for the prevention of physiological lactation. [Docket No. 94N-0304.] Fed Regist. 1995; 60:3404-5.

111. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology. 2001; 56:S1-S88.

112. Anon. Initial treatment of Parkinson’s disease: wait just a minute. Med Lett Drugs Ther. 2001; 43:59-60. [PubMed 11445778]

a. Novartis. Parlodel (bromocriptine mesylate) SnapTabs tablets and capsules prescribing information. Suffern, NY; 2006 May.

b. AHFS drug information 2006. McEvoy GK, ed. Bromocriptine mesylate. Bethesda, MD: American Society of Health-System Pharmacists; 2006:3610-4.

c. Schleachte, JA. Prolactinoma. NEJM. 2007; 349;21:2035-41.

More Bromocriptine Mesylate resources

Bromocriptine Mesylate Side Effects (in more detail)
Bromocriptine Mesylate Use in Pregnancy & Breastfeeding
Drug Images
Bromocriptine Mesylate Drug Interactions
Bromocriptine Mesylate Support Group
6 Reviews for Bromocriptine Mesylate - Add your own review/rating

Bromocriptine Prescribing Information (FDA)

bromocriptine Advanced Consumer (Micromedex) - Includes Dosage Information

Bromocriptine MedFacts Consumer Leaflet (Wolters Kluwer)

Cycloset Prescribing Information (FDA)

Cycloset MedFacts Consumer Leaflet (Wolters Kluwer)

Cycloset Consumer Overview

Parlodel Prescribing Information (FDA)

Compare Bromocriptine Mesylate with other medications

Acromegaly
Diabetes, Type 2
Hyperprolactinemia
Parkinson's Disease
Tardive Dyskinesia

bevacizumab Intravenous

be-va-SIZ-yoo-mab

Intravenous route(Solution)

Gastrointestinal perforation, some cases fatal, has occurred in up to 2.4% of bevacizumab-treated patients. Discontinue bevacizumab if gastrointestinal perforation or wound dehiscence occurs. Discontinue at least 28 days prior to elective surgery. Do not initiate bevacizumab for at least 28 days after surgery and until the surgical wound is fully healed. Severe or fatal hemorrhage, including hemoptysis, gastrointestinal bleeding, CNS hemorrhage, and vaginal bleeding, have occurred up to 5-fold more frequently in bevacizumab-treated patients. Do not administer bevacizumab to patients with serious hemorrhage or recent hemoptysis .

Commonly used brand name(s)

In the U.S.

Avastin

Available Dosage Forms:

Solution

Therapeutic Class: Immunological Agent

Pharmacologic Class: Monoclonal Antibody

Uses For bevacizumab

Bevacizumab injection is given with other medicines to treat patients with metastatic (a cancer that has spread) carcinoma of the colon or rectum. bevacizumab is also used to treat a certain type of metastatic lung cancer called non-squamous, non-small cell lung cancer, and a certain type of brain tumor called glioblastoma.

Bevacizumab is a substance that helps the body fight cancer. It prevents the growth of certain types of blood vessels to cancer cells. This helps to decrease the growth of cancer cells by starving the cells of nutrients that are needed to grow.

Bevacizumab is also used in combination with other medicines (e.g., interferon alfa) to treat patients with cancer of the kidney that has spread to other areas of the body.

bevacizumab is to be administered only by or under the immediate supervision of your doctor.

Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, bevacizumab is used in certain patients with the following medical conditions:

Glioblastoma multiforme, recurrent, following prior treatment with temozolomide (used for a certain type of brain cancer that is getting worse or not responding to treatment).

Metastatic colorectal cancer, first-line therapy, in combination with capecitabine and oxaliplatin (used together with other medicines for cancer of the colon or rectum that has spread to other areas of the body).

Before Using bevacizumab

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For bevacizumab, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to bevacizumab or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of bevacizumab injection in the pediatric population. Safety and efficacy have not been established.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of bevacizumab injection in the elderly. However, elderly patients are more likely to have age-related heart or blood vessel problems, which may require caution in patients receiving bevacizumab injection.

Pregnancy

	Pregnancy Category	Explanation
All Trimesters	C	Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Proper Use of bevacizumab

You will receive bevacizumab while you are in a hospital or cancer treatment center. A nurse or other trained health professional will give you bevacizumab. bevacizumab is given through a needle placed in one of your veins.

Bevacizumab is often given together with other cancer medicines. If you are using a combination of medicines, make sure that you take each one at the proper time and do not mix them. Ask your doctor to help you plan a way to remember to take your medicines at the right times.

Precautions While Using bevacizumab

It is very important that your doctor check your progress at regular visits to make sure that bevacizumab is working properly and to check for unwanted effects. Your doctor will need to check your urine and blood pressure at regular visits while you are receiving bevacizumab. Be sure to keep all appointments. You may be taught how to check your blood pressure at home.

Using bevacizumab while you are pregnant can harm your unborn baby. Use two forms of birth control to keep from getting pregnant. Keep using two forms of birth control for at least 6 months after your treatment ends. If you think you have become pregnant while using the medicine, tell your doctor right away.

bevacizumab may affect the way your body heals from cuts and wounds. Make sure any doctor who treats you knows that you are using bevacizumab. You may need to stop using bevacizumab several weeks before and after having surgery.

bevacizumab may increase your chance of having bleeding problems. Stop using bevacizumab and tell your doctor right away if you start to notice any signs of bleeding.

bevacizumab may increase your chance of having blood clots or a brain condition called reversible posterior leukoencephalopathy syndrome (RPLS). Stop using bevacizumab and tell your doctor right away if you develop chest pain, sudden and severe headaches, fainting spells, seizures, unusual drowsiness, confusion, or problems with vision, speech, or walking while you are using bevacizumab.

Tell your doctor right away if you are having severe stomach pain accompanied by other symptoms such as constipation, fever, nausea, and vomiting. These could be symptoms of a serious medical condition.

bevacizumab may also increase your risk of having a serious condition called tracheoesophageal fistula (an abnormal opening in one or more places between the esophagus and the trachea). Tell your doctor right away if you start having trouble swallowing, coughing, or choking while eating, trouble breathing, or chest pain or discomfort while you are using bevacizumab.

Bevacizumab can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. It can also lower the number of platelets, which are necessary for proper blood clotting. If this occurs, there are certain precautions you can take, especially when your blood count is low, to reduce the risk of infection or bleeding:

If you can, avoid people with infections. Check with your doctor immediately if you think you are getting an infection or if you get a fever or chills, cough or hoarseness, lower back or side pain, or painful or difficult urination.

Check with your doctor immediately if you start to cough up blood or if you notice any unusual bleeding or bruising; black, tarry stools; blood in the urine or stools; or pinpoint red spots on your skin.

Be careful when using a regular toothbrush, dental floss, or toothpick. Your medical doctor, dentist, or nurse may recommend other ways to clean your teeth and gums. Check with your medical doctor before having any dental work done.

Do not touch your eyes or the inside of your nose unless you have just washed your hands and have not touched anything else in the meantime.

Be careful not to cut yourself when you are using sharp objects such as a safety razor or fingernail or toenail cutters.

Avoid contact sports or other situations where bruising or injury could occur.

Bevacizumab may cause a serious side effect called an infusion reaction. This can be life-threatening and requires immediate medical attention. Tell your doctor or nurse right away if you have fever, chills, trouble with breathing, lightheadedness, fainting, or chest pain within a few hours after you receive it.

If you plan to have children, talk with your doctor before using bevacizumab. Some women using bevacizumab have become infertile (unable to have children).

bevacizumab Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur:

More common

Black, tarry stools

bleeding gums

body aches or pain

burning, tingling, numbness, or pain in the hands, arms, feet, or legs

chest pain or discomfort

chills

cloudy urine

convulsions

cough

cracks in the skin

decreased urine output

difficult or labored breathing

dilated neck veins

dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position

ear congestion

extreme fatigue

fever

high blood pressure

irregular breathing

irregular heartbeat

lack or loss of strength

lightheadedness

loss of appetite

loss of heat from the body

loss of voice

mood changes

nasal congestion

nervousness

pain

pain, redness, or swelling in the arm or leg

painful or difficult urination

pinpoint red spots on the skin

pounding in the ears

rapid breathing

redness

runny nose

sensation of pins and needles

shortness of breath

slow or fast heartbeat

sore throat

sores on the skin

sores, ulcers, or white spots on the lips or in the mouth

stabbing pain

sunken eyes

sweating

swelling of the face, fingers, feet, or lower legs

swelling or inflammation of the mouth

swollen glands

thirst

tightness in the chest

trouble with breathing

unusual bleeding or bruising

unusual tiredness or weakness

vomiting of blood or material that looks like coffee grounds

watery or bloody diarrhea

weight gain

wheezing

wrinkled skin

yellow skin

Less common

Abdominal or stomach pain

bone pain

difficulty having a bowel movement (stool)

difficulty with swallowing

fainting

severe constipation

severe vomiting

stomach tenderness

Rare

Back pain

blisters

blurred vision

coma

confusion

dizziness

drowsiness

headache

increased thirst

muscle pain or cramps

open sores

pale skin

Incidence not known

Bloody mucus or unexplained nosebleeds

hoarseness

sudden weakness in the arms or legs

sudden, severe chest pain

voice changes

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Acid or sour stomach

belching

bloody nose

change in taste or bad unusual or unpleasant (after) taste

change in walking and balance

clumsiness or unsteadiness

diarrhea

dry mouth

excess flow of tears

hair loss

heartburn

indigestion

low blood pressure

stomach discomfort, upset, or pain

thinning of the hair

weight loss

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: bevacizumab Intravenous side effects (in more detail)

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More bevacizumab Intravenous resources

Bevacizumab Intravenous Side Effects (in more detail)
Bevacizumab Intravenous Use in Pregnancy & Breastfeeding
Bevacizumab Intravenous Drug Interactions
Bevacizumab Intravenous Support Group
6 Reviews for Bevacizumab Intravenous - Add your own review/rating

Compare bevacizumab Intravenous with other medications

Breast Cancer
Breast Cancer, Metastatic
Colorectal Cancer
Glioblastoma Multiforme
Macular Degeneration
Malignant Glioma
Neurofibromatosis
Non-Small Cell Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Renal Cell Carcinoma
Solid Tumors

Wednesday, September 21, 2016

Baby Lotion

Generic Name: topical emollients (TOP i kal ee MOL i ents)

Brand Names: Aloe Vesta Cream, AlphaSoft, AmeriPhor, Aqua Glycolic, Aqua Lube, Aquaphor, Aveeno, Baby Lotion, Baby Oil, Bag Balm, Baza-Pro, Beta Care, Blistex Lip Balm, Carmex, CarraKlenz, CeraVe, CeraVe AM, Cetaphil Lotion, Chap Stick, Citraderm, CoolBottoms, Corn Huskers Lotion, Curel Moisture Lotion, Derma Soothe, Dr Scholl's Essentials Cracked Skin Repair, Eucerin, Herpecin-L, K-Y Jelly, Keri Lotion, Lamisilk Heel Balm, Lubri-Soft, Lubriderm, Mederma, Moisturel, Natural Ice, NeutrapHor, NeutrapHorus Rex, Neutrogena Cleansing, Neutrogena Lotion, Nivea, Nutraderm, Pacquin, Phisoderm, Pretty Feet & Hands, Proshield Skincare Kit, Remedy 4-in-1 Cleansing Lotion, Replens, Secura, Sensi-Care, Soft Sense, St. Ives, Theraplex Lotion, Vaseline Intensive Care

What are Baby Lotion (topical emollients)?

Emollients are substances that moisten and soften your skin.

Topical (for the skin) emollients are used to treat or prevent dry skin. Topical emollients are sometimes contained in products that also treat acne, chapped lips, diaper rash, cold sores, or other minor skin irritation.

There are many brands and forms of topical emollients available and not all are listed on this leaflet.

Topical emollients may also be used for purposes not listed in this medication guide.

What is the most important information I should know about Baby Lotion (topical emollients)?

You should not use a topical emollient if you are allergic to it. Topical emollients will not treat or prevent a skin infection.

Ask a doctor or pharmacist before using this medication if you have deep wounds or open sores, swelling, warmth, redness, oozing, bleeding, large areas of skin irritation, or any type of allergy.

What should I discuss with my healthcare provider before using Baby Lotion (topical emollients)?

You should not use a topical emollient if you are allergic to it. Topical emollients will not treat or prevent a skin infection.

Ask a doctor or pharmacist if it is safe for you to use this medicine if you have:

deep wounds or open sores;

swelling, warmth, redness, oozing, or bleeding;

large areas of skin irritation;

any type of allergy; or

if you are pregnant or breast-feeding.

How should I use Baby Lotion (topical emollients)?

Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended.

Clean the skin where you will apply the topical emollient. It may help to apply this product when your skin is wet or damp. Follow directions on the product label.

Shake the product container if recommended on the label.

Apply a small amount of topical emollient to the affected area and rub in gently.

If you are using a stick, pad, or soap form of topical emollient, follow directions for use on the product label.

Do not use this product over large area of skin. Do not apply a topical emollient to a deep puncture wound or severe burn without medical advice.

If your skin appears white or gray and feels soggy, you may be applying too much topical emollient or using it too often.

Some forms of topical emollient may be flammable and should not be used near high heat or open flame, or applied while you are smoking.

Store as directed away from moisture, heat, and light. Keep the bottle, tube, or other container tightly closed when not in use.

What happens if I miss a dose?

Since this product is used as needed, it does not have a daily dosing schedule. Seek medical advice if your condition does not improve after using a topical emollient.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking Baby Lotion (topical emollients)?

Avoid getting topical emollients in your eyes, nose, or mouth. If this does happen, rinse with water. Avoid exposure to sunlight or tanning beds. Some topical emollients can make your skin more sensitive to sunlight or UV rays.

Baby Lotion (topical emollients) side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Stop using the topical emollient and call your doctor if you have severe burning, stinging, redness, or irritation where the product was applied.

Less serious side effects are more likely, and you may have none at all.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Baby Lotion (topical emollients)?

It is not likely that other drugs you take orally or inject will have an effect on topically applied products. But many drugs can interact with each other. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

More Baby Lotion resources

Baby Lotion Use in Pregnancy & Breastfeeding
0 Reviews for Baby - Add your own review/rating

Biafine Emulsion MedFacts Consumer Leaflet (Wolters Kluwer)

Campath Monograph (AHFS DI)

Campral Monograph (AHFS DI)

Camptosar Monograph (AHFS DI)

Diabinese Monograph (AHFS DI)

Kinerase Cream MedFacts Consumer Leaflet (Wolters Kluwer)

Neosalus Foam MedFacts Consumer Leaflet (Wolters Kluwer)

Promiseb Cream MedFacts Consumer Leaflet (Wolters Kluwer)

Compare Baby Lotion with other medications

Dry Skin

Where can I get more information?

Your pharmacist can provide more information about topical emollients.

Cefurim eco

Cefurim eco may be available in the countries listed below.

Ingredient matches for Cefurim eco

Cefuroxime

Cefuroxime axetil (a derivative of Cefuroxime) is reported as an ingredient of Cefurim eco in the following countries:

Switzerland

International Drug Name Search

BroveX ADT

Generic Name: brompheniramine and phenylephrine (BROM fen IR a meen and FEN il EFF rin)

Brand Names: Alacol, Alenaze-D, Alenaze-D NR, B-Vex D, BPM PE, Brom Tann PE, Bromfed, Bromfed-PD Capsules, BroveX ADT, BroveX PEB, Brovex-D, Children's Cold & Allergy, Dimaphen Elixir, Dimetapp Cold & Allergy, Entre-B, J-Tan D, J-Tan D SR, Phenyl 15/12mg, Phenyl 7.5/6mg, RespaHist II, Rhinabid, Rhinabid PD, Seradex-LA, Tanabid SR, V-Hist, VazoBid, VaZol-D, Vazotab, Zotex-PE

What is BroveX ADT (brompheniramine and phenylephrine)?

Brompheniramine is an antihistamine that reduces the natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.

Phenylephrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).

The combination of brompheniramine and phenylephrine is used to treat nasal congestion, sneezing, itching, watery eyes, and runny nose caused by allergies, hay fever, and the common cold.

Brompheniramine and phenylephrine may also be used for purposes not listed in this medication guide.

What is the most important information I should know about BroveX ADT (brompheniramine and phenylephrine)?

Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children. You should not use this medication if you are allergic to brompheniramine or phenylephrine, or to other decongestants, diet pills, stimulants, or ADHD medications. Do not use brompheniramine and phenylephrine if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.

Ask a doctor or pharmacist about taking brompheniramine and phenylephrine if you have heart disease or high blood pressure, diabetes, a thyroid disorder, glaucoma, kidney disease, an enlarged prostate, or problems with urination.

What should I discuss with my healthcare provider before taking BroveX ADT (brompheniramine and phenylephrine)?

You should not use this medication if you are allergic to brompheniramine or phenylephrine, or to other decongestants, diet pills, stimulants, or ADHD medications. Do not use brompheniramine and phenylephrine if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.

Ask a doctor or pharmacist if it is safe for you to take brompheniramine and phenylephrine if you have:

heart disease or high blood pressure;

diabetes;

a thyroid disorder;

glaucoma;

kidney disease;

an enlarged prostate; or

problems with urination.

FDA pregnancy category C. It is not known whether brompheniramine and phenylephrine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication. Brompheniramine and phenylephrine can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I take BroveX ADT (brompheniramine and phenylephrine)?

Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Cough or cold medicine is usually taken only for a short time until your symptoms clear up.

Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children. Take the medicine with a full glass of water. Do not crush, chew, break, or open an extended-release capsule. Swallow it whole. Breaking or opening the pill may cause too much of the drug to be released at one time.

The chewable tablet must be chewed before you swallow it.

Measure liquid medicine with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.

Shake the oral suspension (liquid) well just before you measure a dose. Do not take brompheniramine and phenylephrine for longer than 7 days in a row. Talk with your doctor if your symptoms do not improve after 7 days of treatment, or if you have a fever with a headache, cough, or skin rash. Store at room temperature away from moisture and heat.

What happens if I miss a dose?

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include feeling restless or nervous, nausea, vomiting, stomach pain, dizziness, drowsiness, dry mouth, warmth or tingly feeling, or seizure (convulsions).

What should I avoid while taking BroveX ADT (brompheniramine and phenylephrine)?

This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.

Avoid becoming overheated or dehydrated during exercise and in hot weather.

Drinking alcohol can increase certain side effects of brompheniramine and phenylephrine. Ask a doctor or pharmacist before using any other cold, cough, allergy, or pain medicine. Antihistamines and decongestants are contained in many combination medicines. Taking certain products together can cause you to get too much of a certain drug. Check the label to see if a medicine contains an antihistamine or decongestant.

Avoid taking this medication if you also take diet pills, caffeine pills, or other stimulants (such as ADHD medications). Taking a stimulant together with a decongestant can increase your risk of unpleasant side effects.

BroveX ADT (brompheniramine and phenylephrine) side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have a serious side effect such as:

fast, pounding, or uneven heartbeat;

severe dizziness, anxiety, restless feeling, or nervousness;

easy bruising or bleeding, unusual weakness, fever, chills, body aches, flu symptoms;

nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or

dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath, uneven heartbeats, seizure).

Less serious side effects may include:

drowsiness or dizziness;

blurred vision;

dry mouth, nose, or throat;

mild stomach pain, constipation;

problems with memory or concentration;

feeling restless or excited (especially in children);

sleep problems (insomnia); or

warmth, redness, or tingly feeling under your skin.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect BroveX ADT (brompheniramine and phenylephrine)?

Before using brompheniramine and phenylephrine, tell your doctor if you regularly use other medicines that make you sleepy (such as cold or allergy medicine, sedatives, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused by brompheniramine and phenylephrine.

Tell your doctor about all other medications you are using, especially:

medicines to treat high blood pressure;

a beta blocker such as atenolol (Tenormin, Tenoretic), carvedilol (Coreg), labetalol (Normodyne, Trandate), metoprolol (Dutoprol, Lopressor, Toprol), nadolol (Corgard), propranolol (Inderal, InnoPran), sotalol (Betapace), and others; or

antidepressants such as amitriptyline (Elavil), clomipramine (Anafranil), imipramine (Janimine, Tofranil), and others.

This list is not complete and other drugs may interact with brompheniramine and phenylephrine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

More BroveX ADT resources

BroveX ADT Side Effects (in more detail)
BroveX ADT Use in Pregnancy & Breastfeeding
BroveX ADT Drug Interactions
BroveX ADT Support Group
0 Reviews for BroveX ADT - Add your own review/rating

Alenaze-D Elixir MedFacts Consumer Leaflet (Wolters Kluwer)

Bromfed MedFacts Consumer Leaflet (Wolters Kluwer)

BroveX-D Suspension MedFacts Consumer Leaflet (Wolters Kluwer)

Entre-B Prescribing Information (FDA)

J-Tan D Chewable Tablets MedFacts Consumer Leaflet (Wolters Kluwer)

Rhinabid Sustained-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer)

Compare BroveX ADT with other medications

Hay Fever
Nasal Congestion
Rhinitis

Where can I get more information?

Your pharmacist can provide more information about brompheniramine and phenylephrine.

See also: BroveX ADT side effects (in more detail)

Tuesday, September 20, 2016

Ophtagen

Ophtagen may be available in the countries listed below.

Ingredient matches for Ophtagen

Gentamicin

Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Ophtagen in the following countries:

Philippines

International Drug Name Search